VISEN Pharmaceuticals (2561.HK)
2561.HK Stock Price Chart
Explore VISEN Pharmaceuticals interactive price chart. Choose custom timeframes to analyze 2561.HK price movements and trends.
2561.HK Company Profile
Discover essential business fundamentals and corporate details for VISEN Pharmaceuticals (2561.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
21 Mar 2025
Employees
58.00
Website
https://www.visenpharma.com/cnCEO
An-bang Lu
Description
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare. The company was incorporated in 2018 and is headquartered in Suzhou, China.
2561.HK Financial Timeline
Browse a chronological timeline of VISEN Pharmaceuticals corporate events including earnings releases, dividend announcements, and stock splits.
2561.HK Stock Performance
Access detailed 2561.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.